198480 EGAPP recommendations: Implications for public health providers

Tuesday, November 10, 2009: 10:30 AM

Cecelia A. Bellcross, PhD, MS, CGC , Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA
Daurice A. Grossniklaus, RN, MEd, PhD , Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA
Jennifer L. Flome, MPH , McKing Contractor to Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA
Stephanie Melillo, MPH , McKing Contractor to Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA
Michele Reyes, PhD, MS , Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA
The Evaluation of Genetics in Practice and Prevention (EGAPP) initiative was launched by the CDC's Office of Public Health Genomics in 2004 to establish and evaluate a systematic, evidence-based process for assessing genetic tests and other applications of genomic technology in transition from research to clinical and public health practice. The independent, non-federal EGAPP working group recently published three new recommendations regarding current genetic testing applications: genetic testing for Lynch syndrome in individuals with newly diagnosed colorectal cancer; UGT1A1 genotyping and treatment of metastatic colorectal cancer; and gene expression profiling to improve outcomes in breast cancer patients. This presentation will provide an overview of the EGAPP initiative and methods, background on the health conditions addressed in the recommendations, basic information on the genetic testing technology employed, and discussion of potential implications to clinical practice. Translated EGAPP recommendation materials developed for patients and providers will be presented, including ways in which public health professionals can assist in ensuring appropriate translation, dissemination, and evaluation to maximize population health benefit.

Learning Objectives:
1) Describe the goals and methodology of the Evaluation of Genetics in Practice and Prevention (EGAPP) initiative. 2) Explain the implications of recent EGAPP recommendations for providers and the public. 3) Evaluate methods of translation and dissemination of EGAPP recommendations toward maximizing population health benefit.

Keywords: Genetics, Evidence Based Practice

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have 18 years experience as a clinical genetics counselor, and recently completed a doctorate in Population Health at the University of Wisconsin-Madison. I am currently a CDC/ASHG Public Health Genetics fellow in the Office of Public Health Genomics. I am working with the EGAPP initiative, specifically to translate existing EGAPP recommendations for provider/payer/consumer use, as well as to assist in the development of new reviews/recommendations regarding advancing genomic technologies.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.